Effects of Low-Dose and Very Low-Dose Ketamine among Patients with Major Depression: A Systematic Review and Meta-Analysis

International Journal of Neuropsychopharmacology

Volumn 19, Issue 4, 2016, Pages

  Xu, Ying ^a   Hackett, Maree ^a   Carter, Gregory ^b   Loo, Colleen ^c   Gálvez, Verònica ^c   Glozier, Nick ^a   Glue, Paul ^d   Lapidus, Kyle ^e   McGirr, Alexander ^f   Somogyi, Andrew A ^g   Mitchell, Philip B ^c   Rodgers, Anthony ^a  

^a UNIVERSITY OF SYDNEY   (Australia)

^b UNIVERSITY OF NEWCASTLE   (Australia)

^c UNIVERSITY OF NEW SOUTH WALES   (Australia)

^d UNIVERSITY OF OTAGO   (New Zealand)

^e STONY BROOK UNIVERSITY   (United States)

^f UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^g UNIVERSITY OF ADELAIDE   (Australia)

Author keywords

Ketamine; major depression; meta analysis

Indexed keywords

KETAMINE; ANTIDEPRESSANT AGENT;

BRADYCARDIA; DELUSION; DISEASE SEVERITY; DISSOCIATIVE DISORDER; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; HALLUCINATION; HUMAN; HYPOTENSION; LOW DRUG DOSE; MAJOR DEPRESSION; META ANALYSIS; PARANOIA; PRIORITY JOURNAL; PSYCHOPHARMACOTHERAPY; RANDOMIZED CONTROLLED TRIAL (TOPIC); REMISSION; REVIEW; SUICIDE; SUICIDE ATTEMPT; SYSTEMATIC REVIEW; TACHYCARDIA; TREATMENT RESPONSE; COMPARATIVE STUDY; DEPRESSIVE DISORDER, MAJOR;

ANTIDEPRESSIVE AGENTS; DEPRESSIVE DISORDER, MAJOR; HUMANS; KETAMINE; RANDOMIZED CONTROLLED TRIALS AS TOPIC;

EID: 84966349654     PISSN: 14611457     EISSN: 14695111     Source Type: Journal    
DOI: 10.1093/ijnp/pyv124     Document Type: Review

References (40)

1. aan het Rot M, Collins Ka, Murrough JW, Perez AM, Reich DL, Charney DS, Mathew SJ (2010) Safety and efficacy of repeated-dose intravenous ketamine for treatment-resistant depression. Biol Psychiatry 67:139-145.
2. Aan Het Rot M, Zarate Ca, Charney DS, Mathew SJ (2012) Ketamine for depression: where do we go from here? Biol Psychiatry 72:537-547.
3. Aitken RC (1969) Measurement of feelings using visual analogue scales. Proc R Soc Med 62:989.
4. Argiriadou H, Himmelseher S, Papagiannopoulou P, Georgiou M, Kanakoudis F, Giala M, Kochs E (2004) Improvement of pain treatment after major abdominal surgery by intravenous S+-ketamine. Anesth Analg 98:1413-1418, table of contents.
5. Autry AE, Adachi M, Nosyreva E, Na ES, Los MF, Cheng P-f, Kavalali ET, Monteggia LM (2011) NMDA receptor blockade at rest triggers rapid behavioural antidepressant responses. Nature 475:91-95.
6. Berman RM, Cappiello a, Anand a, Oren Da, Heninger GR, Charney DS, Krystal JH (2000) Antidepressant effects of ketamine in depressed patients. Biol Psychiatry 47:351-354.
7. Bremner JD, Krystal JH, Putnam FW, Southwick SM, Marmar C, Charney DS, Mazure CM (1998) Measurement of dissociative states with the clinician-administered dissociative states scale (CADSS). J Trauma Stress 11:125-136.
8. Brittner M, Micoulaud-Franchi JA, Richieri R, Boyer L, Adida M, Lancon C, Fond G (2014) [Ketamine in acute and severe major depressive disorder]. Presse Med 43:492-500.
9. Caddy C, Giaroli G, White TP, Shergill SS, Tracy DK (2014) Ketamine as the prototype glutamatergic antidepressant: pharmacodynamic actions, and a systematic review and meta-analysis of efficacy. Ther Adv Psychopharmacol 4:75-99.
10. Chong C, Schug SA, Page-Sharp M, Jenkins B, Ilett KF (2009) Development of a sublingual/oral formulation of ketamine for use in neuropathic pain: preliminary findings from a three-way randomized, crossover study. Clin Drug Investig 29:317-324.
11. Diazgranados N, Ibrahim L, Brutsche NE, Newberg A, Kronstein P, Khalife S, Kammerer WA, Quezado Z, Luckenbaugh DA, Salvadore G, Machado-Vieira R, Manji HK, Zarate CA Jr (2010a) A randomized add-on trial of an N-methyl-D-aspartate antagonist in treatment-resistant bipolar depression. Arch Gen Psychiatry 67:793-802.
12. DiazGranados N, Ibrahim La, Brutsche NE, Ameli R, Henter ID, Luckenbaugh Da, Machado-Vieira R, Zarate Ca (2010b) Rapid resolution of suicidal ideation after a single infusion of an N-methyl-D-aspartate antagonist in patients with treatment-resistant major depressive disorder. J Clin Psychiatry 71:1605-1611.
13. Ghasemi M, Kazemi MH, Yoosefi A, Ghasemi A, Paragomi P, Amini H, Afzali MH (2014) Rapid antidepressant effects of repeated doses of ketamine compared with electroconvulsive therapy in hospitalized patients with major depressive disorder. Psychiatry Res 215:355-361.
14. Hamilton M (1960) Rating scale for depression. J Neurol Neurosur PS 23:56-62.
15. Higgins JPT, Green S (editors) (2009) Cochrane handbook for systematic reviews of interventions version 5.0.2 [updated September 2009]. The Cochrane Collaboration, 2009. Available from www.cochrane-handbook.org.
16. Katalinic N, Lai R, Somogyi A, Mitchell PB, Glue P, Loo CK (2013) Ketamine as a new treatment for depression: a review of its efficacy and adverse effects. Aust N Z J Psychiatry 47:710-727.
17. Kudoh A, Takahira Y, Katagai H, Takazawa T (2002) Small-dose ketamine improves the postoperative state of depressed patients. 114-118.
18. Lai R, Katalinic N, Glue P, Somogyi AA, Mitchell PB, Leyden J, Harper S, Loo CK (2014) Pilot dose-response trial of i.v. ketamine in treatment-resistant depression. World J Biol Psychiatry 0:1-6.
19. Lapidus KA, Levitch CF, Perez AM, Brallier JW, Parides MK, Soleimani L, Feder A, Iosifescu DV, Charney DS, Murrough JW (2014) A randomized controlled trial of intranasal ketamine in major depressive disorder. Biol Psychiatry 76:970-976.
20. Larkin GL, Beautrais AL (2011) A preliminary naturalistic study of low-dose ketamine for depression and suicide ideation in the emergency department. Int J Neuropsychopharmacol 14:1127-1131.
21. Martinowich K, Jimenez DV, Zarate CA, Manji HK (2013) Rapid antidepressant effects: moving right along. Mol Psychiatry 18:856-863.
22. McGirr A, Berlim MT, Bond DJ, Fleck MP, Yatham LN, Lam RW (2014) A systematic review and meta-analysis of randomized, double-blind, placebo-controlled trials of ketamine in the rapid treatment of major depressive episodes. Psychological Medicine FirstView:1-12.
23. Montgomery SA, Asberg M (1979) A new depression scale designed to be sensitive to change. Br J Psychiatry 134:382-389.
24. Murrough J, Soleimani L, DeWilde K, Collins K, Lapidus K, Iacoviello B, Lener M, Kautz M, Kim J, Stern J (2015) Ketamine for rapid reduction of suicidal ideation: a randomized controlled trial. Psychological medicine 1-10.
25. Murrough JW, Iosifescu DV, Chang LC, Al Jurdi RK, Green CE, Perez AM, Iqbal S, Pillemer S, Foulkes A, Shah A, Charney DS, Mathew SJ (2013) Antidepressant efficacy of ketamine in treatment-resistant major depression: a two-site randomized controlled trial. Am J Psychiatry 170:1134-1142.
26. Overall JE, Gorham DR (1962) The brief psychiatric rating scale. Psychol Rep 10:799-812.
27. Paul R, Schaaff N, Padberg F, Möller H-J, Frodl T (2009) Comparison of racemic ketamine and S-ketamine in treatment-resistant major depression: report of two cases. World J Biol Psychiatry 10:241-244.
28. Price RB, Nock MK, Charney DS, Mathew SJ (2009) Effects of intravenous ketamine on explicit and implicit measures of suicidality in treatment-resistant depression. Biol Psychiatry 66:522-526.
29. Rasmussen KG, Lineberry TW, Galardy CW, Kung S, Lapid MI, Palmer BA, Ritter MJ, Schak KM, Sola CL, Hanson AJ, Frye MA (2013) Serial infusions of low-dose ketamine for major depression. J Psychopharmacol 27:444-450.
30. RevMan (2014) The Nordic Cochrane Centre, The Cochrane Collaboration. Review Manager (RevMan). 5.3. Copenhagen: The Nordic Cochrane Centre, The Cochrane Collaboration, 2014.
31. Rodriguez CI, Kegeles LS, Levinson A, Feng T, Marcus SM, Vermes D, Flood P, Simpson HB (2013) Randomized controlled crossover trial of ketamine in obsessive-compulsive disorder: proof-of-concept. Neuropsychopharmacology 38:2475-2483.
32. Senn S (2002) Crossover trials in clinical research: John Wiley & Sons.
33. Shiroma PR, Johns B, Kuskowski M, Wels J, Thuras P, Albott CS, Lim KO (2014) Augmentation of response and remission to serial intravenous subanesthetic ketamine in treatment resistant depression. J Affect Disord 155:123-129.
34. Sos P, Klirova M, Novak T, Kohutova B, Horacek J, Palenicek T (2013) Relationship of ketamine's antidepressant and psychotomimetic effects in unipolar depression. Neuro Endocrinol Lett 34:287-293.
35. Valentine GW, Mason GF, Gomez R, Fasula M, Watzl J, Pittman B, Krystal JH, Sanacora G The antidepressant effect of ketamine is not associated with changes in occipital amino acid neurotransmitter content as measured by [1H]-MRS. Psychiatry Res. 2011 February 28; 191(2): 122-127.
36. Whiteford HA, Ferrari AJ, Degenhardt L, Feigin V, Vos T (2015) The global burden of mental, neurological and substance use disorders: an analysis from the global burden of disease study 2010. PLoS ONE 10:e0116820.
37. Young R, Biggs J, Ziegler V, Meyer D (1978) A rating scale for mania: reliability, validity and sensitivity. Br J Psychiatry 133:429-435.
38. Zarate CA, Brutsche NE, Ibrahim L, Franco-Chaves J, Diazgranados N, Cravchik A, Selter J, Marquardt Ca, Liberty V, Luckenbaugh Da (2012) Replication of ketamine's antidepressant efficacy in bipolar depression: a randomized controlled addon trial. Biol Psychiatry 71:939-946.
39. Zarate CA Jr, Singh JB, Carlson PJ, Brutsche NE, Ameli R, Luckenbaugh DA, Charney DS, Manji HK (2006) A randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression. Arch Gen Psychiatry 63:856-864.
40. Zarate CA Jr, Brutsche N, Laje G, Luckenbaugh DA, Venkata SLV, Ramamoorthy A, Moaddel R, Wainer IW (2012) Relationship of ketamine's plasma metabolites with response, diagnosis, and side effects in major depression. Biol Psychiatry 72:331-338.